Department of Electronics, Carleton University, Ottawa, ON, Canada.
Cardiovascular Devices Division, University of Ottawa Heart Institute, Ottawa, ON, Canada.
Artif Organs. 2020 Jul;44(7):680-692. doi: 10.1111/aor.13659. Epub 2020 Mar 8.
To review and analyze the clinical outcomes of thermal therapy (≤1.4°C increase in core body temperature) in patients with heart failure (HF). A systematic review and meta-analysis regarding the effects of thermal therapy on HF was done by searching PubMed, Ovid Medline, Ovid Embase, Scopus, and internal databases up to date (2019). Improvement in the New York Heart Association (NYHA) class: Ten studies with 310 patients showed significant improvement in NYHA class. Only 7 among 40 patients remained in Class IV and 99 patients in Class III from 155 patients. Increased patients in lower classes indicate that more patients showed improvement. Sixteen studies on 506 patients showed an overall improvement of 4.4% of left ventricular ejection fraction (LVEF). Four studies reported improved endothelial dysfunction by 1.7% increase in flow-mediated dilation (FMD) on 130 patients. Reduction in blood pressure: Thermal therapy reduced both systolic blood pressure (SBP) and diastolic blood pressure by 3.1% and 5.31%, respectively, in 431 patients of 15 studies. Decrease in cardiothoracic ratio (CTR): Eight studies reported an average of 5.55% reduction of CTR in a total of 347 patients. Improvement in oxidative stress markers: Plasma brain natriuretic peptide (BNP) levels significantly decreased (mean difference of 14.8 pg/dL) in 303 patients of 9 studies. Improvement of quality of life: Among 65 patients, thermal therapy reduced cardiac death and rehospitalization by 31.3%. A slight increase in core body temperature is a promising, noninvasive, effective, and complementary therapy for patients with HF. Further clinical studies are recommended.
回顾和分析心力衰竭(HF)患者热疗(核心体温升高≤1.4°C)的临床疗效。通过检索 PubMed、Ovid Medline、Ovid Embase、Scopus 和内部数据库(截至 2019 年),对热疗对 HF 影响的相关研究进行了系统评价和荟萃分析。纽约心脏协会(NYHA)心功能分级改善:10 项研究共 310 例患者显示 NYHA 心功能分级显著改善。155 例患者中,仅有 7 例仍为 IV 级,99 例为 III 级。较低心功能分级的患者数量增加表明更多患者病情改善。16 项研究共 506 例患者的左心室射血分数(LVEF)总体改善了 4.4%。4 项研究共 130 例患者报告称,血流介导的舒张功能(FMD)增加了 1.7%,内皮功能障碍得到改善。血压降低:热疗使 15 项研究共 431 例患者的收缩压(SBP)和舒张压(DBP)分别降低了 3.1%和 5.31%。心胸比(CTR)降低:8 项研究共 347 例患者报告 CTR 平均降低了 5.55%。氧化应激标志物改善:9 项研究共 303 例患者的血浆脑钠肽(BNP)水平显著降低(平均差值为 14.8pg/dL)。生活质量改善:在 65 例患者中,热疗使心脏死亡和再住院率降低了 31.3%。核心体温的轻微升高是一种有前途的、非侵入性的、有效的、对心力衰竭患者具有补充作用的治疗方法。建议进一步开展临床研究。